Aksef

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aksef

Aksef: The Definitive Overview

Property Description
Active Ingredient Cefuroxime
Form Tablets, Oral Suspension, Injection Powder
Pharmacological Class Second-generation Cephalosporin Antibiotic
General Purpose To kill susceptible bacteria causing infection
Origin Semisynthetic

What Type of Medicine is Aksef? (Identity and Classification)

Aksef is a prescription antibiotic medicine whose active ingredient is Cefuroxime, classified as a semisynthetic beta-lactam antibiotic. Cefuroxime belongs to the second-generation cephalosporin class. Aksef is a medicine specifically designed to fight and eliminate bacterial infections. Cefuroxime functions as a broad-spectrum agent, active against a significant range of bacterial pathogens. This positioning makes it a frequent choice when addressing common bacterial illnesses.

Active Ingredient and Available Forms (Composition and Structure)

The active substance in Aksef is Cefuroxime, supplied in different chemical forms tailored for its route of administration. For oral consumption, the drug is formulated as Cefuroxime Axetil, an inactive prodrug that the body converts into the active Cefuroxime compound upon absorption. In contrast, for administration via injection (intramuscular or intravenous), the drug is prepared as Cefuroxime Sodium powder. This dual chemical approach determines the available dosage forms, which include film-coated tablets and granules for oral suspension. The availability of both oral and injectable parenteral forms allows for flexible transitions in patient care.

How Does Aksef Generally Benefit the Body? (High-Level Purpose)

Aksef provides a general benefit by working as a bactericidal agent, meaning it directly kills the infectious bacteria. This effect is achieved by the Cefuroxime molecule interfering with the final stages of bacterial cell wall synthesis. The substance is characterized by its ability to resist inactivation by certain beta-lactamase enzymes. This chemical stability provides a differentiating factor by ensuring the medication remains active against otherwise resistant strains. The primary purpose is to address the root cause of bacterial illness, ensuring the rapid and definitive resolution of susceptible bacterial infections.

What side effects are possible with Aksef?

Possible Side Effects and Safety Information

Aksef (Cefuroxime) is a cephalosporin antibiotic. Its official safety profile is based on data from clinical trials and post-marketing surveillance, classified by major governmental regulatory authorities.

Adverse Reactions Summary

Classification Common Reactions (geq1% of patients) Serious Reactions (Rare, but clinically significant)
System-Organ Classes Gastrointestinal, Nervous System, Blood and Lymphatic System Immune System, Gastrointestinal, Skin
Examples Diarrhea, Nausea/Vomiting, Headache, Dizziness, Eosinophilia, Transient increase in liver enzymes Anaphylaxis and other severe hypersensitivity reactions, Clostridioides difficile-associated diarrhea (CDAD), Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Haemolytic anaemia

Safety Restrictions and Limitations

Hypersensitivity: Aksef is contraindicated in patients with a known severe hypersensitivity reaction (e.g., anaphylaxis) to any beta-lactam antibacterial agent (including penicillins and carbapenems). Caution is advised in patients with a history of non-severe allergy to other beta-lactam drugs.

Gastrointestinal Risk: Use requires caution in patients with a history of gastrointestinal disease, particularly colitis, due to the risk of CDAD, which may occur during or up to two months after treatment.

Drug Interactions: Drugs that reduce gastric acidity (e.g., antacids containing aluminum or magnesium, H2 antagonists) may decrease the bioavailability of the oral formulation and should be monitored. There is a documented risk of decreased effectiveness of some oral contraceptives.

Monitoring Notes: Treatment should be immediately discontinued if a severe allergic reaction or severe, persistent diarrhea occurs. Laboratory tests may show a positive Coombs' test, which can interfere with blood cross-matching procedures. Prolonged use may lead to the overgrowth of non-susceptible organisms, including Candida.

Overdose and Emergency Response

Aksef Overdose and When to Seek Help

Information regarding Aksef overdose is derived directly from official government regulatory documents, outlining the documented clinical effects and the necessary emergency response.

Documented Manifestations and Serious Outcomes

An overdose of Aksef has been officially associated with specific clinical presentations. These typically involve Gastrointestinal disturbances (such as nausea, vomiting, and diarrhea) and Central Nervous System effects (including headache, confusion, and tremor).

Regulatory warnings emphasize the potential for serious or life-threatening outcomes, which may include status epilepticus (sustained seizures) and significant signs of hepatic or renal dysfunction requiring specialized care. Management of overdose is primarily symptomatic and supportive, as official labeling indicates no specific antidote is currently recognized.

Required Emergency Action

Immediate emergency medical care must be sought for any suspected or confirmed overdose of Aksef.

Regulatory documents stipulate that a suspected overdose, regardless of the amount taken or the severity of initial symptoms, requires urgent professional evaluation. The official guidance requires the immediate cessation of the drug and rapid implementation of supportive measures, such as monitoring of vital signs and laboratory parameters (renal and hepatic function) for an extended period of time to manage the drug's known toxicities. Special attention and enhanced monitoring are noted for the pediatric population and patients with pre-existing renal impairment, who may be at a heightened risk for severe outcomes.

Therapeutic Uses of Aksef

Aksef may be part of symptomatic management applied for bacterial infections and provides supportive relief during acute symptomatic episodes. The medication is applicable across several key therapeutic domains.

The medication is commonly used to help manage conditions characterized by periods of heightened symptoms related to respiratory infections (such as bronchitis, bacterial sinusitis, and tonsillitis), localized infections (like uncomplicated UTIs and skin infections), and specific presentations like early Lyme disease. Its use is relevant in clinical settings that involve acute or unstable symptom patterns, and may be applied in situations involving mild-to-moderate episodes up to the heightened systemic burden associated with severe infections like septicemia and meningitis.

“The intended purpose of this supportive relief is to assist with maintaining functional stability during difficult episodes.”

This supportive use assists with maintaining functional stability when symptoms become more noticeable or when risk is increased, such as in its part of symptomatic management applied for prevention of infection after certain surgical procedures.

Quick Fact: Relief for Acute Discomfort
Contributes to easing the overall symptom load in conditions involving inflammatory or irritative states (e.g., ear pain, fever, redness, and painful urination).

Eligibility and Restrictions for Use

Aksef (cefuroxime) is an antibiotic prescribed to treat a variety of bacterial infections. It is not effective against viral infections, such as the common cold or flu. Like all medications, Aksef is suitable for most, but not all, patients.

Who Can Use Aksef?

Aksef is typically used in adults and children aged three months and older for susceptible bacterial infections. It is generally considered safe for use during pregnancy and breastfeeding, though a healthcare provider must weigh the benefits against any potential risks and monitor the infant for side effects like diarrhea or yeast infection.

Who Should Not Use Aksef? (Contraindications)

The primary absolute contraindication is a known allergy to cefuroxime or any other cephalosporin antibiotics (e.g., cephalexin, ceftriaxone) or to any of the drug's other ingredients. A severe allergic reaction can be life-threatening.

Aksef should be used with caution, and may require dosage adjustment or alternative treatment, in patients with certain pre-existing conditions:

Condition Reason for Caution
History of severe diarrhea or colitis May worsen the condition.
Kidney problems Slower clearance may lead to drug build-up.
Phenylketonuria (PKU) The oral liquid suspension may contain phenylalanine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aksef (Cefuroxime) has officially documented interaction patterns that are primarily categorized by how they modify the antibiotic's concentration in the body or introduce pharmacodynamic risk, as described in regulatory documents.


Official Interaction Statements

Interacting Agent / Class Documented Interaction Effect Restriction or Requirement
Probenecid Increases systemic exposure by inhibiting renal excretion. Not Recommended for co-administration.
Acid-Reducing Drugs (Antacids, PPIs, H2-Blockers) Lower the bioavailability of Cefuroxime Axetil oral form. Mandatory separation from short-acting antacids.
Oral Contraceptives May reduce the efficacy of estrogen-containing contraceptives. Potential for reduced efficacy is noted in regulatory labels.
Potent Diuretics / Nephrotoxic Drugs Increased risk of nephrotoxicity with high dosages of Cefuroxime. Caution advised, especially in patients with impaired renal function.
Oral Anticoagulants Concomitant use may be associated with increased International Normalised Ratio (INR). Monitoring for changes in blood clotting is implied.
Food (Oral Suspension) Food enhances absorption and systemic exposure. Must be given with food for maximum absorption.

Interaction Context Constraints

Official labeling requires specific procedural constraints when using Aksef. Drugs that reduce gastric acidity should be administered with a timing separation from Cefuroxime Axetil tablets to mitigate reduced absorption. Conversely, the oral suspension must be administered with food to achieve optimal drug levels. The concomitant use of the transporter inhibitor Probenecid is not recommended because it increases the antibiotic’s concentration in the bloodstream. The overall structure is defined by restrictions that maintain adequate drug exposure and manage additive risks.

Mechanism of Action

Irreversible Disruption of Bacterial Cell Wall Structure

The active compound, Cefuroxime, functions as an inhibitor by targeting specific bacterial enzymes known as Penicillin-Binding Proteins (PBPs), particularly PBP3, which are necessary for the final cross-linking of the peptidoglycan cell wall structure. Cefuroxime forms a covalent bond with the active site of these enzymes, causing their permanent, irreversible inhibition. The resulting failure to construct a rigid, protective wall leads to the inability of the bacterium to withstand its internal osmotic pressure, initiating the mechanistic cascade of cellular lysis (rupture) and death.

Activation via Targeted Prodrug Conversion

Aksef is administered as an inactive compound, the prodrug Cefuroxime Axetil, which is designed for enhanced absorption into the systemic circulation. Once absorbed, it is chemically broken down (hydrolyzed) by the body's esterase enzymes, releasing the fully active Cefuroxime molecule. This activation cascade ensures that a consistent concentration of the active compound is distributed throughout the body, prepared for molecular interaction with bacterial targets. This mechanism is constrained by bacterial beta-lactamase enzymes, which can hydrolyze the drug's core structure and prevent PBP binding.

Dosage and Administration Information

How to Use Aksef: Official Administration Guidelines

Aksef, which contains the active ingredient Cefuroxime, is administered according to protocols defined by its chemical form and the severity of the infection. The medicine is available as the prodrug Cefuroxime Axetil for oral use (tablets and suspension) and as Cefuroxime Sodium for parenteral use (intravenous or intramuscular injection).


Administration and Dosage Regimens

The standard adult regimen for most oral uses is 250 mg every 12 hours, though higher oral doses of 500 mg every 12 hours are specified for certain infections, such as early Lyme disease. Injectable use typically requires 750 mg every 8 hours (three times daily), with this dose increasing to 1.5 g every 8 hours for severe systemic infections. Treatment courses are generally duration-specific, ranging from 7 to 10 days for uncomplicated issues, and extending up to 20 days for specific conditions.


Administration Conditions and Adjustments

The oral suspension form is taken with food to maximize the absorption of Cefuroxime Axetil, while the film-coated tablets can be administered without regard to meals. A critical procedural instruction is that tablets are swallowed whole and not crushed, broken, or chewed. Dosing is also subject to population-specific adjustments; for patients with impaired renal function, the interval between parenteral doses is extended to prevent medicine accumulation. For children, the oral dose is calculated based on body weight, typically 20–30 mg/kg/day divided into two doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aksef (Cefuroxime)


Evidence for Use in Respiratory and Upper Airway Infections

Studies for Pharyngitis and Tonsillitis

Research exploring the use of Aksef for throat and tonsil infections is based on short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were conducted across both pediatric patients (including young children) and adults. The primary focus of researchers was to monitor the resolution of acute symptoms, such as fever and throat pain, and to measure whether the target bacteria, primarily Group A Streptococcus, were cleared. Studies report patterns observed in the populations where, following the standard course, measurements of changes in clinical status and bacteriological clearance were generally noted.

Studies for Bronchitis and Sinusitis

For the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB), clinical trials have explored outcomes in adult patients. These studies primarily monitored the alleviation of cough and changes in sputum, while also attempting to measure the eradication of the infectious bacteria. Research also focused on identifying outcomes related to different treatment durations. Findings describe patterns of changes in clinical status and changes in symptom intensity across the observed populations, with results generally assessed up to 30 days post-treatment. What remains uncertain for both conditions is the generalizability of older trial findings due to evolving regional patterns of antibiotic resistance. Additionally, data for severe or complicated cases of sinusitis remain limited.


Evidence for Use in Localized Infections

Research for Uncomplicated Urinary Tract Infections (UTIs)

The evidence for the use of Aksef in uncomplicated UTIs was studied for both adults and adolescents. Controlled clinical trials were evaluated over a standard course duration. The key outcomes that studies monitored included the attainment of a measured clinical endpoint (resolution of painful urination and urgency) and Bacteriological Clearance (negative urine culture). Findings generally described the measurements of both clinical and bacteriological outcomes reported at the post-treatment follow-up visit.

Research for Prevention of Surgical Site Infections

Research in this area is based on Randomized Clinical Trials and specialized pharmacokinetic studies. These studies, which included Randomized Clinical Trials, were conducted in adults undergoing specific surgical procedures. The research examined two main factors: the incidence of Post-Surgical Infections (SSI) in the 30 days following the procedure, and the drug's concentration in tissue to ensure it reached therapeutic levels during the operation. Findings show patterns related to the reported frequency of surgical site infection (SSI) endpoints when the drug was administered according to specific, optimized protocols.

Key Studies & References Cefuroxime: Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Aksef (FAQ)


Q: Are there any specific foods or drinks I should avoid while taking Aksef?

A: Regulatory documents note that the use of alcohol or tobacco with Cefuroxime may lead to interactions. Additionally, certain medications that reduce stomach acid, such as antacids, can decrease the absorption of the oral formulation. Official instructions note that the oral suspension must be taken with food to ensure proper absorption.


Q: How likely is it to have an allergic reaction to Aksef?

A: Serious, occasionally fatal hypersensitivity reactions (severe allergic reactions) have been reported, though they are generally considered rare. The risk of these reactions is higher in individuals who have a known history of sensitivity to beta-lactam antibacterial drugs, such as penicillins.


Q: Is Aksef the same as its generic version?

A: Aksef is the brand name for the active ingredient Cefuroxime. For oral use, the medicine is supplied as Cefuroxime Axetil, which is the official generic name. Regulatory documents confirm that the active substance in Aksef is Cefuroxime.


Q: What are the signs of a serious allergic reaction to Aksef that I should watch for?

A: Signs of severe allergic reactions (hypersensitivity) reported include skin rash, itching, hives, and swelling of the face, lips, tongue, or throat. Official guidance states that treatment is typically discontinued immediately if any signs of a severe allergic reaction occur.


Q: Can people with a known penicillin allergy safely take Aksef?

A: Cefuroxime Axetil is officially contraindicated (should not be used) for patients with a known severe hypersensitivity reaction to any beta-lactam antibacterial drug, which includes penicillins. Regulatory information notes that individuals with a history of penicillin sensitivity have experienced severe reactions when treated with cephalosporins.


Q: Why are the treatment times for Aksef different depending on the condition?

A: The defined duration of Cefuroxime Axetil treatment varies because it is specifically determined by the type and severity of the bacterial infection being treated. Official guidelines establish different treatment lengths (e.g., 7 days versus 20 days) based on clinical trial data to ensure the infection is fully resolved.


Q: Is it safe to stop taking Aksef once I feel better?

A: Regulatory guidance describes that the full prescribed course of the medication is intended to be taken, even if symptoms begin to improve early. Stopping therapy too soon may decrease the medication's effectiveness and increase the likelihood that bacteria will develop resistance.


Q: How common is it to feel dizzy after taking Aksef?

A: Dizziness is listed among the common side effects reported in clinical trials for Aksef, meaning it occurs in 1% or more of patients. Because dizziness is reported, caution is generally indicated for activities that require concentration.


Q: Can Aksef cause a secondary yeast infection?

A: Official precautions note that prolonged or repeated use of Cefuroxime Axetil may result in the overgrowth of non-susceptible microorganisms, including the fungus Candida. Candida overgrowth is the cause of common yeast infections.


Q: Does the time of day matter when taking Aksef?

A: Official dosing is typically directed by the requirement to take the medicine at a specific interval, such as every 12 hours. Additionally, the oral suspension form is administered with food to achieve the optimal level of drug absorption.


Q: What does 'resistance' mean in the context of Aksef?

A: Antibiotic resistance occurs when bacteria develop ways to overcome the effects of the medicine. Official documentation indicates that bacteria can cause resistance by breaking down Cefuroxime using enzymes called beta-lactamase or by altering the drug's target site.


Q: Does Aksef interact with common non-prescription pain relievers like ibuprofen or acetaminophen?

A: Official drug interaction information notes that the excretion rate of acetaminophen (paracetamol) may be affected when combined with Cefuroxime. The decision on whether to use Cefuroxime with other medications is determined by a healthcare provider.


Q: What should I do if I forget or miss a dose of Aksef?

A: Official patient guidance states that if a dose is missed, taking it as soon as possible is described. If it is almost time for the next scheduled dose, taking only that dose is described, and patients should not take a double or extra dose.


Q: How long does Aksef stay in your system after I finish the prescription?

A: The elimination half-life of Cefuroxime is approximately 80 minutes (1.3 hours) in adults. The half-life is the time it takes for the amount of active drug in the body to be reduced by half. It takes several half-lives for the drug to be fully cleared from the body.


Q: Does Aksef carry a risk of causing confusion or hallucinations?

A: Post-marketing surveillance has reported rare central nervous system effects, including confusion or seizures. The evaluation of any unusual effects, like confusion, is typically conducted by a healthcare provider.


Q: Does Aksef affect blood sugar levels?

A: Official warnings note that Cefuroxime Axetil may cause a false-positive result for sugar in the urine when tested using copper reduction methods. The selection of appropriate glucose testing methods during treatment is a decision made in consultation with the patient’s care team.


Q: What is the evidence regarding Aksef use in the elderly?

A: Cefuroxime has been tested in the elderly population and has not been shown to cause significantly different side effects or problems than in younger adults. However, the use of this medicine in older patients often requires careful monitoring due to their potential susceptibility to side effects.


Q: How long after taking Aksef can I take iron supplements?

A: Iron products and other supplements containing minerals may interfere with the body's absorption of Cefuroxime Axetil. Regulatory patient guidance describes the practice of spacing the intake of mineral-containing products, such as iron, at least two hours after the antibiotic dose.


Q: What happens if I accidentally take two doses of Aksef too close together?

A: Patient instructions strictly advise against taking double or extra doses. Official regulatory guidance describes contacting a Poison Control Center or seeking immediate emergency medical help if an overdose is suspected.

How should Aksef be stored and disposed of?

Storage and Disposal Conditions for Aksef (Cefuroxime Axetil)

Official instructions define specific handling and storage requirements to maintain product stability.

Storage Requirements

Dosage Form Temperature and Protection Stability Constraint
Tablets Store at controlled room temperature (20 C to 25 C) and protect from moisture. Do not freeze. Keep in a tightly closed container.
Suspension (Reconstituted) Store under refrigeration (2 C to 8 C). Discard any unused portion after 10 days.

Disposal and Safety

All forms of Aksef must be stored out of the sight and reach of children. Unused or expired medication should be disposed of via a drug take-back program. If a take-back program is unavailable, mix the medicine with an unappealing substance and place it in a sealed container for disposal with household trash. The product must not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aksef found in:

A-Z Index: